DASATINIB IN TREATING YOUNG PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS OR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR CHRONIC MYELOGENOUS LEUKEMIA THAT DID NOT RESPOND TO IMATINIB MESYLATE: